{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=13", "query": { "intervention": "Saline 0.9%", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1512, "total_pages": 152, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T10:03:59.588Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05283980", "title": "Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pain, Postoperative", "Pain, Acute", "Pain, Chest", "Pain", "Satisfaction, Patient", "Opioid Use, Unspecified", "Opioids; Harmful Use" ], "interventions": [ { "name": "0.25% Bupivacaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2022-11-17", "completion_date": "2024-03-29", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283980" }, { "nct_id": "NCT03970447", "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Paxalisib", "type": "DRUG" }, { "name": "VAL-083", "type": "DRUG" }, { "name": "VT1021", "type": "DRUG" }, { "name": "Troriluzole", "type": "DRUG" }, { "name": "ADI-PEG 20", "type": "BIOLOGICAL" }, { "name": "AZD1390", "type": "DRUG" }, { "name": "Tinostamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Global Coalition for Adaptive Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2250, "start_date": "2019-07-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 42, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970447" }, { "nct_id": "NCT03897998", "title": "Neural Correlates of Hypoalgesia Driven by Observation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain", "Virtual Reality", "Placebo" ], "interventions": [ { "name": "Naloxone", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 211, "start_date": "2021-11-01", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03897998" }, { "nct_id": "NCT01449721", "title": "Preemptive Resuscitation for Eradication of Septic Shock", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sepsis", "Severe Sepsis" ], "interventions": [ { "name": "Intravenous fluid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Christiana Care Health Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2011-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-10-04", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 5, "location_summary": "Newark, Delaware • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01449721" }, { "nct_id": "NCT07473128", "title": "Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Limited Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Saline (0.9% NaCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacosmos A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-09", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07473128" }, { "nct_id": "NCT02577614", "title": "FEIBA and Use of Blood Products in Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "FEIBA", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 12, "start_date": "2016-02", "completion_date": "2020-03", "has_results": false, "last_update_posted_date": "2020-07-14", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02577614" }, { "nct_id": "NCT03617367", "title": "Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Dystonia" ], "interventions": [ { "name": "daxibotulinumtoxinA for injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Revance Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 357, "start_date": "2018-09-05", "completion_date": "2021-05-25", "has_results": false, "last_update_posted_date": "2022-01-28", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03617367" }, { "nct_id": "NCT02677298", "title": "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glabellar Frown Lines" ], "interventions": [ { "name": "Botulinum Toxin A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Croma-Pharma GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 784, "start_date": "2016-03-02", "completion_date": "2017-11-16", "has_results": true, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Encino, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encino", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677298" }, { "nct_id": "NCT04824092", "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tafasitamab placebo", "type": "DRUG" }, { "name": "Lenalidomide placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 899, "start_date": "2021-05-11", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 47, "location_summary": "Daphne, Alabama • Anaheim, California • Clovis, California + 44 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04824092" }, { "nct_id": "NCT03988023", "title": "Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Osteoarthritis of the Knee" ], "interventions": [ { "name": "Ampion", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ampio Pharmaceuticals. Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 1043, "start_date": "2019-06-24", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-20T10:03:59.588Z", "location_count": 1, "location_summary": "Englewood, Colorado", "locations": [ { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03988023" } ] }